Hansen K W, Klein F, Christensen P D, Sørensen K, Andersen P H, Møller J, Pedersen E B, Christiansen J S, Mogensen C E
Department of Medicine M. (Diabetes & Endocrinology) Aarhus Kommunehospital, Denmark.
Diabete Metab. 1994 Sep-Oct;20(5):485-93.
To study the effect of Captopril on ambulatory blood pressure, renal and cardiac function and extracellular volume in microalbuminuric Type 1 diabetic patients.
Randomized, double blind placebo controlled study of two years duration.
University clinic.
Twenty-two patients without hypertension.
Patients received 50 mg Captopril or placebo twice a day.
Ambulatory blood pressure, renal function, extracellular volume, and echocardiographic indices of cardiac function and dimensions were assessed annually. Clinic blood pressure and urinary albumin excretion were measured every 3 months.
Twenty-four hour mean arterial blood pressure was unchanged in the Captopril group (mean +/- SD) (baseline 93 +/- 4 and follow up 91 +/- 8 mmHg) and in the placebo group (96 +/- 7 and 97 +/- 10 mmHg, NS). Night/day ratio of blood pressure was unaffected. Glomerular filtration rate was unchanged and renal plasma flow increased in the Captopril (557 +/- 97 and 600 +/- 112 ml min-1) versus the placebo group (574 +/- 85 and 535 ml min-1, p = 0.05). Filtration fraction was reduced in the Captopril versus the placebo group (p < 0.05). Extracellular volume and echocardiographically derived parameters were unaffected. The relative change in day time mean arterial blood pressure in the Captopril group correlated with changes in urinary albumin excretion (Spearmans r = 0.85, p < 0.05) unlike clinic mean arterial blood pressure (r = 0.33, p = 0.35).
Diurnal rhythm of blood pressure was unaffected by long term administration of Captopril. Renal plasma flow was increased and filtration fraction reduced. A significant association between changes in urinary albumin excretion and blood pressure after Captopril was revealed only by the implementation of ambulatory blood pressure measurements.
研究卡托普利对微量白蛋白尿的1型糖尿病患者动态血压、肾功能、心脏功能及细胞外容量的影响。
为期两年的随机、双盲、安慰剂对照研究。
大学诊所。
22例无高血压患者。
患者每日两次服用50毫克卡托普利或安慰剂。
每年评估动态血压、肾功能、细胞外容量以及心脏功能和大小的超声心动图指标。每3个月测量诊室血压和尿白蛋白排泄量。
卡托普利组24小时平均动脉血压无变化(均值±标准差)(基线时为93±4,随访时为91±8 mmHg),安慰剂组也无变化(96±7和97±10 mmHg,无显著差异)。血压的昼夜比未受影响。与安慰剂组相比,卡托普利组的肾小球滤过率无变化,但肾血浆流量增加(分别为557±97和600±112 ml/min与574±85和535 ml/min,p = 0.05)。卡托普利组的滤过分数低于安慰剂组(p < 0.05)。细胞外容量和超声心动图得出的参数未受影响。与诊室平均动脉血压不同,卡托普利组日间平均动脉血压的相对变化与尿白蛋白排泄量的变化相关(斯皮尔曼相关系数r = 0.85,p < 0.05)(诊室平均动脉血压r = 0.33,p = 0.35)。
长期服用卡托普利不影响血压的昼夜节律。肾血浆流量增加,滤过分数降低。仅通过动态血压测量才揭示出卡托普利治疗后尿白蛋白排泄量变化与血压之间存在显著关联。